Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAXIPEM: axitinib +/- pembrolizumab in first-line treatment for type 2 papillary renal cell carcinoma
2024-513986-38-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in renal cell carcinoma (RCC) comparing Axitinib monotherapy with Axitinib + pembrolizumab (2 arms). Primary endpoint: Objective response rate (ORR). Planned start Oct 2024; status: authorised.
02
Drugs
pembrolizumabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-513986-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513986-38-00.